During a Case-Based Roundtable® event, John N. Allan, MD, discussed how new regimens using BTK inhibitors and venetoclax might be used in patients with chronic lymphocytic leukemia.

Azercabtagene zapreleucel has been granted fast track designation from the FDA for the treatment of diffuse large B-cell lymphoma.

In patients who were pretreated and treatment naïve with RET fusion-positive NSCLC, selpercatinib yielded an ORR of 61.5% and 82.6%, respectively.

R. Lor Randall, MD, FACS, discusses the application of a bioengineered bone marrow matrix as a three-dimensional model to analyze osteosarcoma cell behavior under varying oxygen tensions.

Jeffery Zonder, MD, discusses the need for increased awareness in multiple myeloma.

Wojciech Jurczak, MD, PhD, ​​discusses the future of B-cell lymphoma therapy, with a focus on Bruton's tyrosine kinase inhibitors and degraders.

A real-world study showed OS outcomes with eribulin similar to those with trabectedin in doxorubicin-pretreated patients with advanced liposarcoma.

Paul B. Renz, DO, discusses anecdotal changes observed by clinician researchers using the MR-LINAC system.

A propensity-score matched cohort study found a significantly reduced risk of recurrence of bladder cancer in patients who had blue light vs white light cystoscopy.

Benjamin Herzberg, MD, details research in KRAS G12C-mutated NSCLC with divarasib and how he currently selects between available therapies in this space.

Results from the RAINIER trial showed that mipletamig, venetoclax, and azacitidine achieved a complete remission rate of 90% in patients with AML.

Moffitt Cancer Center researchers found a way to boost cancer immunotherapy by targeting a protein called macrophage receptor with collagenous structure.

The FDA has cleared EVM14, making it the first mRNA therapeutic cancer vaccine for global clinical trials.

A Type II variation application has been submitted to the EMA for the expanded approval of sugemalimab for unresectable stage III NSCLC.

The adverse effect profile was similar among patients with prostate cancer using NeuroSAFE-assisted RARP vs standard RARP.

Paul B. Renz, DO, discusses the ideal uses of magnetic resonance-guided linear accelerator system.

For Nutrition Awareness Month, we highlight the importance of tailoring dietary strategies to patients with cancer to improve outcomes and quality of life.

The combination of toripalimab and bevacizumab has been approved in China for the treatment of patients with unresectable or metastatic HCC.

Raajit Rampal, MD, PhD, discusses current JAK inhibitor treatment options for myelofibrosis and additional therapies being evaluated in clinical trials.

Clara Bodelon, PhD, MS, discussed her recently published study which found that the greatest physical health declines in patients who survived breast cancer stemmed from chemotherapy.

Jill Gilbert, MD, discusses professional strategy techniques that she has found useful through incredibly challenging times.

A recent study suggests that using artificial intelligence to measure tumor size could reduce treatment failures by more than 70%.

Experts discuss how to decide which robotic prostatectomy (RP) approach to utilize, considering factors such as patient characteristics, surgical outcomes, and the latest clinical evidence.

Experts discuss the role of PARP inhibitors in prostate cancer treatment, exploring their mechanisms, clinical benefits, and how they fit into current therapeutic strategies.

Experts discuss considerations for other androgen receptor inhibitors, highlighting their role in treatment strategies and how they impact patient outcomes in prostate cancer.

Experts give an overview of the treatment landscape in prostate cancer as of 2025.

A panelist discusses how recent advancements in molecular diagnostics, targeted therapies, and individualized treatment approaches give them greatest optimism for patients with polycythemia vera (PV) by potentially altering disease trajectory, reducing complications, and significantly improving quality of life and long-term outcomes.

Experts share clinical pearls on synthesizing risk assessment and response patterns in the management of advanced renal cell carcinoma.

Panelists discuss how medical professionals balance maximizing progression-free survival with preserving future treatment options by considering disease biology, resistance mechanisms, and patient factors. At first progression, the NCCN recommends continuing current therapy or switching to amivantamab with a platinum doublet, based on mutation status, prior response, toxicity, and patient preferences.

Panelists discuss how the choice between chimeric antigen receptor T-cell (CAR T) therapy and autologous stem cell transplantation (auto-SCT) requires careful evaluation of multiple patient-specific factors. Medical professionals consider disease type and stage, prior treatments, patient age and fitness, cytogenetic risk, donor availability, and timing. CAR T may be preferred for relapsed/refractory cases, whereas transplant remains standard for eligible newly diagnosed patients.

Panelists discuss how patient-specific characteristics in diffuse large B-cell lymphoma significantly impact chimeric antigen receptor T-cell (CAR T) therapy outcomes, suggesting that standardized treatment algorithms may need refinement. Factors like tumor biology, immune status, and genetic profiles could help optimize therapeutic selection and sequencing.